INTRODUCTION
diabetes. In both methods, insufficient biocompatibility with development of an avascular capsule around the implant, leading to impaired graft survival, is a signifi-Encapsulation of cellular transplants in a semipermeable immunoprotective membrane can provide an op-cant problem (5,11). Until recently, encapsulation has mainly been evalu-portunity for transplantation, without the need for immunosuppression. Two main methods are available: 1) ated for transplantation of the islets of Langerhans. However, encapsulated cellular transplants may also be macroencapsulation-in which a large number of cells are placed in an immunoprotective device, and 2) micro-used to cure other types of endocrine deficiencies (1, 10, 12, 13, 17) . One such group comprises patients with chronic encapsulation-in which small clusters of cells are surrounded by a gel capsule, usually consisting of alginate.
hypoparathyroidism following parathyroid or thyroid surgery. Most of these patients can be well managed The macroencapsulation devices have better physical stability and are easy to retrieve, but the size of the de-with vitamin D and calcium supplements. In a few cases, the calcium levels are unstable and patients have signifi-vice necessary to hold a sufficient number of cells may be a serious disadvantage in some conditions, including cant clinical problems with hypocalcemic or hypercalce-592 TIBELL ET AL. mic episodes. However, the high-dose immunosuppressive therapy required for an allogeneic transplant is rarely, if ever, justified in such patients. Encapsulation may then provide a valuable alternative. In this study, we evaluated the use of a macroencapsulation device for transplantation of human parathyroid tissue. The aim of the autologous implant study was to determine whether human parathyroid tissue could survive in the physiological environment in the device. The aim of the allogeneic implant study was to evaluate survival of human encapsulated parathyroid tissue in the presence of an allo-response.
MATERIALS AND METHODS
The studies were approved by the Human Ethics Committee and Animal Ethics Committee at Karolinska Institutet, Stockholm, Sweden.
The Immunoisolating Membrane and the Device Designs
The parathyroid tissue was encapsulated in a bilay- ner tighter membrane provided immunoprotection, while the outer membrane was chosen for its ability to induce neovascularization (7,11). On the outside, a nonwoven ene port provides access to the lumen for loading. To polyester mesh (Saati, Como, Italy) was added to imload the TheraCyte TM device through the narrow port, prove stability. Experimental studies in rodents indicate the tissue must be more finely divided than required for that this membrane can protect allografts from rejection loading of Boggs devices. After mincing with micro-(8,18). scissors, the parathyroid tissue was meshed through a In this clinical trial, two types of macroencapsulation steel net, with a pore size of 250 µm, into RPMI culture devices constructed from this membrane were used. The medium. The tissue homogenate is then centrifuged at so-called Boggs device (Baxter Healthcare, Round Lake, 1200 rpm for 2 min, and the pellet loaded into a Hamil-IL) was used in the autologous implant study, while in ton syringe and transferred to the device. After loading, the following allogeneic study a new design was used:
the port is sealed with glue (Silastic  , medical adhesive the TheraCyte TM device. The devices are shown in Figsilicon type A, Dow Corning Corporation, Midland, MI, ure 1. In the rounded Boggs device, the two membrane USA). The filled devices are kept in RPMI, pending imsheets are separated by a silicon ring to create a lumen. plantation. The time between surgical removal from the The construct is placed in a titanium ring housing to donors and implantation in the recipients ranged beprovide stability. The Boggs device is 6 mm in diameter tween 2 and 3 h. In this study, two internal volume sizes and approximately 0.12 mm thick. The theoretical inner were used, 4.5-and 40-µl devices. volume of the device is 4.8 µl. The tissue was prepared Autologous Parathyroid Transplantation Study by mincing with micro-scissors and then loaded onto the lower membrane, using a pipette. The upper membrane
In patients operated on for parathyroid hyperplasia, we routinely remove all four parathyroid glands and was placed on the top with the silicon ring in between and, finally, the two titanium rings were pressed to-then reimplant approximately 80-100 mg parathyroid tissue into the brachio-radial muscle of the forearm. Six gether.
The TheraCyte TM device (Baxter Healthcare) was such patients were included in this study. All received an additional implant of their own parathyroid tissue en-used in the allogeneic transplant study. This prefabricated device has a rectangular, tea bag-like, shape. The capsulated in a Boggs device and implanted SC into the forearm. One patient with parathyroid adenoma was also two membrane sheets have been welded together using ultrasonic energy. At one end of the device, a polyethyl-included and received her own encapsulated adenoma-tous tissue SC. The devices were explanted after 2-4 mation was observed. There was only minimal bleeding during device removal. Samples were placed in Histo-weeks for histological evaluation.
fix TM (Histolab Products AB, Västra Frölunda, Sweden).
Allogeneic Parathyroid Transplantation Study
Control Implants in Nude Mice In this study, four patients with chronic hypoparathyroidism and unstable calcium levels, in spite of pharma-
The devices in the nude mice experiments were of two kinds. When the nude mouse was used as a control cological treatment, were implanted with macroencapsulated allogeneic parathyroid tissue. The recipients had for a patient in the autologous study, the mouse and the patient both received Boggs devices. When the nude previously undergone operations for primary hyperparathyroidism (patients 1 and 3), nodular nontoxic goiter mouse was used as a control in the allogeneic study, the mouse as well as the patient both received TheraCyte TM (patient 2), and papillary thyroid carcinoma (patient 4). All the patients had repeatedly been shown to have devices. In five of the seven autologous implant cases and in three of the four allogeneic implant cases, a nude lower calcium levels than the reference value and undetectable or very low PTH concentrations. All received mouse was transplanted with encapsulated parathyroid tissue from the same donor as a control. In the other long-term treatment with vitamin D and calcium supplements. The donors were patients undergoing parathy-cases, there was not enough tissue for a control mouse. Nude mice weighing 25-30 g (Balbc/nu, Mollegaard roidectomy because of a parathyroid adenoma (donors 1 and 2) or parathyroid hyperplasia (donors 3 and 4). They
Research and Breeding Center, Ry, Denmark) were used for the implants. These mice are T cell deficient and do were blood group compatible, but HLA mismatched in relation to the recipients. Donors were negative for HIV not reject cellular xenografts. The device was implanted via a 15-mm dorsal midline incision, a SC pocket being and hepatitis B and C. The CMV status was compatible with that of the recipient. created at the side of the incision. The implants in the mice were harvested on the same day as the correspond-Depending on the amount of tissue available, the patients were given one to three 40-µl TheraCyte TM de-ing human implant, after 2-4 weeks in the autologous implant study and after 4 weeks in the allogeneic im-vices, which were implanted SC in the lower arm. The parathyroid tissue was meshed into culture medium and plant cases. The devices were placed in Histofix TM . centrifuged at 1000 rpm for 2 min. The pellet was then Histological Evaluation loaded into a Hamilton syringe. Each 40-µl device was loaded with approximately 40 µl of parathyroid tissue After fixation, the devices were dehydrated using routine methods. Before embedding, they were divided fragments. In addition, a small device holding 4.5 µl was implanted SC and removed at 4 weeks to evaluate centrally and the cut surfaces were placed upwards in the block.
Step sections, approximately 5 µm thick, were early changes in the implanted tissue. One patient did not have enough tissue for a small device. The patients cut and stained with hematoxylin and eosin. All sections were qualitatively evaluated with the light microscope received no immunosuppressive drugs.
by the same investigator. In addition, in the autologous The Implantation Procedure implant study, a semiquantitative estimate of parathyroid tissue, fibrosis, and necrosis was made. On the section On implantation, a SC pocket was created by blunt containing most tissue, the volume densities (Vv) of dissection. Care was taken not to implant the device dithese parameters were estimated by point-counting in a rectly below the skin incision. The pocket was closed projection microscope (magnification 300×), using a with a reabsorbable SC suture (Vicryl 5-0, Johnson & grid with 2.5 cm between the test points. Results are Johnson Intl., Brussels, Belgium) and the skin was presented as volume fractions (%), mean ± SD. In the closed by an intracutaneous running suture, using the allogeneic implant study, the small devices explanted same material. Dicloxacillin (Diclocil  , Bristol-Myers from patients and nude mice were also evaluated by this Squibb, Bromma, Sweden) was given IV on the day of semiquantitative technique. The presence of viable paraimplantation in a dose of 1 g every 8 h. The patients thyroid cells was verified by immunohistochemistry, usreceiving autologous implants were already under gening an antiserum against human parathyroid hormone 1eral anesthesia for their parathyroid surgery. The other 38 (Peninsula Laboratories Inc., St. Helens, Merseyside, operations were performed under local anesthesia (Ci-England). tanest  , 10 mg/ml, Astra, Södertälje, Sweden), without the use of vasoconstrictors. Explantation of the devices Analysis of Parathyroid Hormone was also performed under local anesthesia, the scar being opened and the device excised with a thin rim of SC Blood samples for analysis of PTH were obtained at least once a week during the first 3 months and then tissue. The surrounding tissue was loosely adherent to the device and, macroscopically, no obvious capsule for-twice monthly. Samples were obtained from the cubital vein in both arms because increased levels of PTH in rounded by an outer ring of fibroblasts. In the five cases where implants were made both in a human and a nude the graft-bearing arm have been reported in patients with autologous grafts IM (15, 25) . The serum levels of PTH mouse, the histological findings were similar. Examples of the histological specimens are shown in Figure 2 . The in the patients were analyzed by an immunoradiometric assay (IRMA, Nichols Institute of Diagnostics, San Juan results of the individual implants are given in Table 1 , expressed as volume fractions (%). Capistrano, CA, USA). This intact PTH assay has a sensitivity of 1 ng/L and a reference interval of 8-51 ng/L.
Allogeneic Implant Study Mixed Lymphocyte Culture (MLC)
In this patient group receiving several larger devices The MLC was performed in the four donor-recipient over a longer period, the implants were also well tolerpairs in the allogeneic study. White blood cells were ated, with no signs of infection or inflammation. Two of isolated from peripheral blood before implantation and the patients were very slim and the devices could be at 9 and 13 months (patient 1), at 9 and 12 months (paseen faintly through the skin. However, no local tendertient 2), at 3, 6, 9, and 12 months (patient 3), and at 3, ness occurred after the first 2 weeks following implanta-6, and 9 months (patient 4). Mononuclear cells were tion. The surrounding tissue remained soft and without stored in a deep freezer in medium containing 10% palpable capsule formation. The macroscopic appear-DMSO, pending use. A pool of MNCs was used as the ances in two patients are shown in Figure 3 . positive control. The tests were performed in a microcul-
The 4.5-µl TheraCyte TM devices explanted at 4 weeks ture system using triplicate cultures with 1.5 × 10 5 viable for early evaluation of tissue survival showed marked recipient cells from the different time points as respondfibrosis in the grafts and only 1%, 5%, and 23% of the ers and the same concentration of donor cells as stimulaimplants, respectively, consisted of viable endocrine tistor cells. The stimulator cells were inactivated by irradisue. Similar findings were observed in the devices haration with 20 Gy. Cultures were incubated in humidified vested from the nude mice, but in two of those grafts air containing 5% CO 2 at 37°C and harvested on day 6 there were also calcium deposits (Fig. 4) . A mild lymph-(24). Each culture was labeled with 2 µCi [ 3 H]thymidine ocytic inflammation was observed around the devices (Amersham, UK) and counted in a beta counter (LKB, harvested from the patients (Fig. 5) . Wallac, Finland). MLC reactivity was expressed as rela-
The large devices were explanted at 14, 13, 11, and tive response (RR). The RR was defined as cpm of [(R + 8.5 months after implantation, respectively. A few clus-Dx) − (R + Rx)/(R + Px) − (R + Rx)] × 100, where P is the ters of surviving parathyroid cells were identified in pooled control, R is recipent cells, D is donor, and X is each patient, but the grafts mainly contained fibrotic tisirradiated fraction. sue (Fig. 6) . The implants were surrounded by a foreign body reaction with fibrosis. In three patients, the lymph-Panel Reactive Antibodies ocytic inflammation around the device was somewhat The presence of lymphocytotoxic antibodies (includincreased compared with after 4 weeks. In patient numing HLA antibodies) was evaluated in patient sera obber 3, the lymphocytic infiltrate at 11 months was more tained before implantation and at explantation. T and B marked. In this case, we could not compare with the cells were separated from 20-25 individuals representfindings at 4 weeks because the amount of tissue had ing different HLA types and used in a panel for screennot sufficed for a control device. However, graft suring of HLA antibodies by a C-dependent microcytotoxic vival was similar to that in the other patients. method. The T and B cells were added to separate wells Before implantation, these patients had low or unand incubated with patient serum and C. The results are measurable levels of parathyroid hormone. No signifipresented as the fraction of wells giving a positive reaccant increase in these levels occurred after transplantion (>25% cytotoxicity) (24).
tation. The patients were initially maintained on their pretransplantation doses of vitamin D and calcium. After RESULTS 2 months, the dose of vitamin D was gradually reduced Autologous Implant Study until the patients became slightly hypocalcemic. The patients were then maintained at this dose for 1-2 months; The implants were well tolerated and no patient developed any clinical or histological signs of infection.
however, this did not affect the PTH levels. Vitamin D and calcium supplements could not be discontinued in The histological evaluation of Boggs devices retrieved from humans and nude mice at 2-4 weeks showed 22 ± any of the patients. Donor-specific mixed lymphocyte reactivity increased 7% vs. 30 ± 11% viable endocrine tissue, 63 ± 7% vs. 51 ± 17% fibrosis, and 15 ± 5% vs. 18 ± 8% necrosis.
in two of the patients. In patient number 1, it was from 25% before implantation to 125% relative activity against Necrotic areas were mainly found in the center of the implants. The viable endocrine cells were often sur-the donor at explantation. In patient number 4, it was from very low levels before the transplant to 10% at 3 months, a maximum of 50% at 6 months, and 40% at 9 months. No significant change occurred in patients number 2 and number 3. Three of the patients had no panel reactive antibodies before the transplantation and they remained negative afterwards. One patient had 70% B cell antibodies before and remained at the same level after transplantation.
DISCUSSION
The survival of an encapsulated allograft depends on at least three variables: the characteristics of the graft, the physiological environment in the device, and the degree of immunoprotection. Obviously, tissues may differ in their physiological demands. Encapsulated as well as nonencapsulated islets of Langerhans usually survive poorly when transplanted SC in mice or humans (6, 16, 22) . Nonencapsulated parathyroid tissue, on the other hand, thrives after SC transplantation into nude mice (4). Furthermore, autotransplantation of human parathyroid tissue into muscle or subcutaneous fat is usually successful when performed during routine parathyroid surgery (3, 25) . The physiological environment and the degree of immunoprotection are related to the properties of the membrane but may also be influenced by the implant site.
The first part of our study indicates that parathyroid tissue can survive for at least 4 weeks when encapsulated in this bilayered membrane and implanted SC in humans. The physiological conditions in the device seemed to meet at least basal requirements for parathyroid tissue because, in the best cases, 35-44% of the implants consisted of viable endocrine cells.
In the allogeneic implants, fibrotic tissue was predominant in all devices that were explanted at 4 weeks. The proportion of endocrine cells was usually lower than in the autografts-in the best case 23%. This may, at least in part, relate to the different method used for tissue preparation. The new design of the device used in the allogeneic implant study aimed at providing a device with defined integrity, which can be loaded without risk of tissue contaminating its outer surface. However, the port allows only passage of small clusters of cells. We believe that the more extensive tissue breakdown required in the allogeneic study disrupted the tissue architecture and may have damaged the cells, thereby making way for the more robust fibroblasts. ters may improve the quality of tissue implanted in the device. The kind of parathyroid tissue used may also influence the outcome. Our experience is too limited for any firm conclusions, but in both studies the best survival was obtained using hyperplastic tissue, while adenomatous tissue seemed to have worse results. Others have reported successful transplantation of normal parathy- cilitate graft survival. The graft depends on the diffusion of oxygen and nutrients from the surrounding microcirculation. In order to improve the exchange across the membrane, the TheraCyte TM device was designed with an outer layer that induces neovascularization of the membrane surface (7). We have recently made in vivo studies on the transport of insulin and glucose across the TheraCyte TM membrane at various times after transplantation (20, 21) . The results indicate that the exchange across the membrane increased significantly about 3 months after implantation. The microcirculatory flow around the device, as evaluated by laser Doppler, increased in parallel (19) . The TheraCyte TM device has a port that permits the device to be filled via a minimal skin incision at any time after implantation. By delaying implantation of the graft, the surface of the device has time to become vascularized, which should improve physiological environment for the encapsulated tissue during the early postimplantation period. membrane and may cause activation of the immune sys-
